FOLH1 and prostate cancer: Positron emission tomography (PET) imaging using radiolabeled ligands targeted at theprostate-specific membrane antigen (PSMA) is increasingly utilized as a diagnosticimaging tool for prostate cancer (PCa), and is the imaging modality of choice inprimary high-risk and biochemically recurrent PCa.1,2 In case of biochemicalrecurrence, the PSMA PET/computed tomography (CT) contributes to early detection ofmetastases at a low prostate-specific antigen (PSA) level leading to managementdecision adjustment in >50% of patients.3,4